Data as of Apr 16
| +1.39 / +2.61%|
The 7 analysts offering 12-month price forecasts for Alnylam Pharmaceuticals Inc have a median target of 108.00, with a high estimate of 125.00 and a low estimate of 65.00. The median estimate represents a +97.77% increase from the last price of 54.61.
The current consensus among 9 polled investment analysts is to Buy stock in Alnylam Pharmaceuticals Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.